VFA
AUPH icon

Virtus Fund Advisers’s Aurinia Pharmaceuticals AUPH Stock Holding History

Virtus Fund Advisers’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$63.1K Buy
7,032
+244
+4% +$1.99K 0.2% 51
2024
Q3 		$49.8K Hold
6,788
– – 0.2% 65
2024
Q2 		$38.8K Buy
+6,788
New +$35.8K 0.15% 74

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Virtus Fund Advisers's AUPH Position: Q4 2024 in Review

Virtus Fund Advisers increased its Aurinia Pharmaceuticals (AUPH) stake by 3.6% in Q4 2024, buying an estimated $1.99K and bringing the position to 7,032 shares worth $63.1K. The position accounts for 0.2% of the portfolio, ranked #51.

Virtus Fund Advisers first reported a position in AUPH in Q2 2024 and has held it in 3 quarters since. 200 funds tracked by Wall St. Rank hold AUPH as of Q4 2024.

  • Virtus Fund Advisers held 7,032 shares of Aurinia Pharmaceuticals worth $63.1K as of Q4 2024.
  • Virtus Fund Advisers bought 244 Aurinia Pharmaceuticals shares in Q4 2024, an estimated $1.99K.
  • Aurinia Pharmaceuticals made up 0.2% of Virtus Fund Advisers's portfolio in Q4 2024, its #51 holding.
  • Virtus Fund Advisers first reported a position in Aurinia Pharmaceuticals in Q2 2024 and has held it in 3 quarters since.
  • 200 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2024.

Based on Virtus Fund Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.